Cancer Research and Treatment

Original Articles

Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer: In Hye Song, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, In Ah Park, Young-Ae Kim, Suk Young Park, Jin Roh, Gyungyub Gong, Hee Jin Lee; Cancer Res Treat. 2017;49(2):399-407. Published online July 27, 2016; DOI: https://doi.org/10.4143/crt.2016.215

Abstract PDF Supplementary Material PubReader ePub

Purpose
The tertiary lymphoid structure (TLS) is an important source of tumor-infiltrating lymphocytes (TILs), which have a strong prognostic and predictive value in triple-negative breast cancer (TNBC). A previous study reported that the levels of CXCL13 mRNA expression were associated with TLSs, but measuring the gene expression is challenging in routine practice. Therefore, this study evaluated the MECA79-positive high endothelial venule (HEV) densities and their association with the histopathologically assessed TLSs in biopsy samples. In addition, the relationship of TLSs with the CXCL13 transcript levels and clinical outcomes were examined.
Materials and Methods
A total of 108 TNBC patients treated with neoadjuvant chemotherapy (NAC) were studied. The amounts of TILs and TLSs were measured histopathologically using hematoxylin and eosin–stained slides. The HEV densities and TIL subpopulations were measured by immunohistochemistry for MECA79, CD3, CD8, and CD20. CXCL13 mRNA expression levels using a NanoString assay (NanoString Technologies).
Results
The mean number of HEVs in pre-NAC biopsies was 12 (range, 0 to 72). The amounts of TILs and TLSs, HEV density, and CXCL13 expression showed robust correlations with each other. A lower pre-NAC clinical T stage, higher TIL and TLS levels, a higher HEV density, CD20-positive cell density, and CXCL13 expression were significant predictors of a pathologic complete response (pCR). Higher CD8-positive cell density and levels of CXCL13 expression were significantly associated with a better disease-free survival rate.
Conclusion
MECA79-positive HEV density in pre-NAC biopsies is an objective and quantitative surrogate marker of TLS and might be a valuable tool for predicting pCR of TNBC in routine pathology practice.

Citations

Citations to this article as recorded by

The discovery of high endothelial venules. A historical note
Domenico Ribatti
Translational Research in Anatomy.2025; 38: 100379. CrossRef
Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer
Yi Xie, Haoxin Peng, Yajie Hu, Keren Jia, Jiajia Yuan, Dan Liu, Yanyan Li, Xujiao Feng, Jian Li, Xiaotian Zhang, Yu Sun, Lin Shen, Yang Chen
BMC Medicine.2025;[Epub] CrossRef
Bi-level graph learning unveils prognosis-relevant tumor microenvironment patterns in breast multiplexed digital pathology
Zhenzhen Wang, Cesar A. Santa-Maria, Aleksander S. Popel, Jeremias Sulam
Patterns.2025; 6(3): 101178. CrossRef
Multifaceted function of B cells in tumorigenesis
Na Kang, Qinghui Duan, Xin Min, Tong Li, Yuxin Li, Ji Gao, Wanli Liu
Frontiers of Medicine.2025; 19(2): 297. CrossRef
Prognostic significance of CD8 + tumor-infiltrating lymphocytes in operable breast cancer: a meta-analysis
Ruijie Niu, Cheng Wang, Yiqun Xie, Shuangshuang Li, Qian Zhao, Yuqing Chang, Zubing Mei
BMC Cancer.2025;[Epub] CrossRef
The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma
Wantao Wu, He Li, Zeyu Wang, Ziyu Dai, Xisong Liang, Peng Luo, Kun Liu, Hao Zhang, Nan Zhang, Shuyu Li, Chi Zhang
Heliyon.2024; 10(1): e23915. CrossRef
Tertiary lymphoid structures, a historical reappraisal
Domenico Ribatti
Tissue and Cell.2024; 86: 102288. CrossRef
Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer
Jinyuan Gu, Jiaming Wang, Yue Sun, Xinrui Mao, Chao Qian, Xinyu Tang, Ji Wang, Hui Xie, Lijun Ling, Yi Zhao, Xiaoan Liu, Kai Zhang, Hong Pan, Shui Wang, Cong Wang, Wenbin Zhou
Cancer Medicine.2024;[Epub] CrossRef
Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Benedetta Donati, Francesca Reggiani, Federica Torricelli, Giacomo Santandrea, Teresa Rossi, Alessandra Bisagni, Elisa Gasparini, Antonino Neri, Laura Cortesi, Guglielmo Ferrari, Giancarlo Bisagni, Moira Ragazzi, Alessia Ciarrocchi
Cancer Immunology Research.2024; 12(1): 120. CrossRef
The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review
Dana Narvaez, Jorge Nadal, Adrian Nervo, María Victoria Costanzo, Claudio Paletta, Fernando E. Petracci, Sergio Rivero, Alexis Ostinelli, Berenice Freile, Diego Enrico, Maria Teresa Pombo, Mora Amat, Edgar Danilo Aguirre, Matias Chacon, Federico Waisberg
Cancers.2024; 16(2): 396. CrossRef
Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer
Timothy B. Fisher, Geetanjali Saini, T. S. Rekha, Jayashree Krishnamurthy, Shristi Bhattarai, Grace Callagy, Mark Webber, Emiel A. M. Janssen, Jun Kong, Ritu Aneja
Breast Cancer Research.2024;[Epub] CrossRef
Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma
Zachary Gao, Joseph Azar, Huili Zhu, Sophia Williams-Perez, Sung Wook Kang, Celia Marginean, Mark P. Rubinstein, Shalini Makawita, Hyun-Sung Lee, E. Ramsay Camp
Frontiers in Immunology.2024;[Epub] CrossRef
Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer
Qianyu Wang, Wentao Zhong, Xiaofei Shen, Zechen Hao, Meng Wan, Xiaopeng Yang, Ran An, Hongyan Zhu, Huiyun Cai, Tao Li, Yuan Lv, Xing Dong, Gang Chen, Aijun Liu, Junfeng Du
npj Precision Oncology.2024;[Epub] CrossRef
Advances in the study of tertiary lymphoid structures in the immunotherapy of breast cancer
Xin Li, Han Xu, Ziwei Du, Qiang Cao, Xiaofei Liu
Frontiers in Oncology.2024;[Epub] CrossRef
Macrophages and tertiary lymphoid structures as indicators of prognosis and therapeutic response in cancer patients
Li Niu, Ting Chen, Aodan Yang, Xiwen Yan, Feng Jin, Ang Zheng, Xinyue Song
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2024; 1879(5): 189125. CrossRef
Peripheral Blood CD8+ T-Lymphocyte Immune Response in Benign and Subpopulations of Breast Cancer Patients
Marek Lenárt, Peter Bober, Miroslav Marcin, Soňa Tkáčiková, Mária Kacírová, Michal Alexovič, Dávid Tóth, Natália Madárová, Jozef Radoňak, Peter Urdzík, Ján Fedačko, Ján Sabo
International Journal of Molecular Sciences.2024; 25(12): 6423. CrossRef
Integrated analysis of multiple transcriptomic approaches and machine learning integration algorithms reveals high endothelial venules as a prognostic immune-related biomarker in bladder cancer
Jinge Zhang, Yuan Huang, Xing Tan, Zihuan Wang, Ranyang Cheng, Shenlan Zhang, Yuwen Chen, Feifan Jiang, Wanlong Tan, Xiaolin Deng, Fei Li
International Immunopharmacology.2024; 136: 112184. CrossRef
Intratumoral high endothelial venules in solid tumors: a pooled study
Bin Wang, Yin Han, Jie Liu, Xinyao Zhang, Yaotiao Deng, Yu Jiang
Frontiers in Immunology.2024;[Epub] CrossRef
B‐cell performance in chemotherapy: Unravelling the mystery of B‐cell therapeutic potential
Zizhuo Li, Anqi Lin, Zhifei Gao, Aimin Jiang, Minying Xiong, Jiapeng Song, Zaoqu Liu, Quan Cheng, Jian Zhang, Peng Luo
Clinical and Translational Medicine.2024;[Epub] CrossRef
Density of tertiary lymphoid structures predicts clinical outcome in breast cancer brain metastasis
Yuan-Yuan Zhao, Zhen Fan, Bao-Rui Tao, Zun-Guo Du, Zhi-Feng Shi
Journal for ImmunoTherapy of Cancer.2024; 12(7): e009232. CrossRef
Tertiary lymphoid structures as potential biomarkers for cancer prediction and prognosis
Xin Zhang, Jie Yao, Mei Xie, Yiran Liang, Xuwen Lin, Jialin Song, Xinyu Bao, Xidong Ma, Yuanyong Wang, Yinguang Zhang, Yiming Liu, Wenya Han, Lei Pan, Xinying Xue
International Immunopharmacology.2024; 140: 112790. CrossRef
Tumor-Infiltrating Lymphocyte Scoring in Neoadjuvant-Treated Breast Cancer
Noémie Thomas, Soizic Garaud, Mireille Langouo, Doïna Sofronii, Anaïs Boisson, Alexandre De Wind, Valérie Duwel, Ligia Craciun, Dennis Larsimont, Ahmad Awada, Karen Willard-Gallo
Cancers.2024; 16(16): 2895. CrossRef
Co-expression network and survival analysis of breast cancer inflammation and immune system hallmark genes
Ayaka Yakushi, Masahiro Sugimoto, Takanori Sasaki
Computational Biology and Chemistry.2024; 113: 108204. CrossRef
Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023
Yiwen Bao, Zeming Mo, Shuang Wang, Jinhua Long, Honghong Zhang, Yujun Xu, Honglian Jiang, Tianbao Qian, Zhu Zeng
Frontiers in Immunology.2024;[Epub] CrossRef
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features
Florence Boissière-Michot, Marie-Christine Chateau, Simon Thézenas, Virginie Lafont, Evelyne Crapez, Priyanka Sharma, Angélique Bobrie, Pascal Roger, Séverine Guiu, William Jacot
Frontiers in Immunology.2024;[Epub] CrossRef
Prognostic value of tumor-infiltrating lymphocyte subtypes and microorganisms in triple-negative breast cancer
Yating Shi, Zhi Guo, Qiang Wang, Huan Deng
Journal of Cancer Research and Therapeutics.2024; 20(7): 1983. CrossRef
The prognostic impact of tumor-infiltrating B lymphocytes in patients with solid malignancies: A systematic review and meta-analysis
Hao Liu, Zhuoqun Li, Xuan Han, Zhujun Li, Yan Zhao, Fenghua Liu, Ziyu Zhu, Yi Lv, Zhijun Liu, Nana Zhang
Critical Reviews in Oncology/Hematology.2023; 181: 103893. CrossRef
Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters
Lixia Zeng, Valerie Cui Yun Koh, Xiao‐Yang Chen, Puay Hoon Tan
Histopathology.2023; 82(5): 779. CrossRef
Can CXCL13 be a prognostic marker in clear cell renal cell carcinoma?
Esma Sayar, Ayşegül Yabacı, Ganime Coban
Indian Journal of Pathology and Microbiology.2023; 66(1): 54. CrossRef
Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review
Brian M. Lam, Clare Verrill
Cancers.2023; 15(4): 1164. CrossRef
B cell‐dependent subtypes and treatment‐based immune correlates to survival in stage 3 and 4 lung adenocarcinomas
Susan Raju Paul, Ivan Valiev, Skylar E. Korek, Vladimir Zyrin, Diana Shamsutdinova, Olga Gancharova, Alexander Zaitsev, Ekaterina Nuzhdina, Diane L. Davies, Ibiayi Dagogo‐Jack, Felix Frenkel, Jessica H. Brown, Joshua M. Hess, Sarah Viet, Jason L. Petersen
FASEB BioAdvances.2023; 5(4): 156. CrossRef
High endothelial venules in cancer: Regulation, function, and therapeutic implication
Gerlanda Vella, Yichao Hua, Gabriele Bergers
Cancer Cell.2023; 41(3): 527. CrossRef
B Cells in Breast Cancer Pathology
Mengyuan Li, Angela Quintana, Elena Alberts, Miu Shing Hung, Victoire Boulat, Mercè Martí Ripoll, Anita Grigoriadis
Cancers.2023; 15(5): 1517. CrossRef
Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
Gyöngyi Munkácsy, Libero Santarpia, Balázs Győrffy
International Journal of Molecular Sciences.2023; 24(8): 6945. CrossRef
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Kevin W. Ng, Jesse Boumelha, Katey S. S. Enfield, Jorge Almagro, Hongui Cha, Oriol Pich, Takahiro Karasaki, David A. Moore, Roberto Salgado, Monica Sivakumar, George Young, Miriam Molina-Arcas, Sophie de Carné Trécesson, Panayiotis Anastasiou, Annika Fend
Nature.2023; 616(7957): 563. CrossRef
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
François Bertucci, Alexandre De Nonneville, Pascal Finetti, Emilie Mamessier
Cancer Communications.2023; 43(8): 943. CrossRef
P16 expression and presence of lymphoid stroma are correlated with good prognosis in mucoepidermoid carcinoma of the head and neck
Yeseul Kim, Joon Seon Song, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim, Kyung-Ja Cho
Pathology - Research and Practice.2023; 251: 154874. CrossRef
The Possible Role of Anti- and Protumor-Infiltrating Lymphocytes in Pathologic Complete Response in Early Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy
Klara Geršak, Blaž Matija Geršak, Barbara Gazić, Andreja Klevišar Ivančič, Primož Drev, Nina Ružić Gorenjec, Cvetka Grašič Kuhar
Cancers.2023; 15(19): 4794. CrossRef
Detection and quantitative analysis of tumor-associated tertiary lymphoid structures
Man Yang, Yurou Che, Kezhen Li, Zengyi Fang, Simin Li, Mei Wang, Yiyao Zhang, Zhu Xu, Liping Luo, Chuan Wu, Xin Lai, Weidong Wang
Journal of Zhejiang University-SCIENCE B.2023; 24(9): 779. CrossRef
Identification of an exosome-related signature associated with prognosis and immune infiltration in breast cancer
Qiaonan Guo, Kelun Pan, Pengjun Qiu, Zundong Liu, Jianpeng Chen, Jianqing Lin
Scientific Reports.2023;[Epub] CrossRef
Association of systemic inflammatory markers and tertiary lymphoid structure with pathological complete response in gastric cancer patients receiving preoperative treatment: a retrospective cohort study
Yingying Wu, Junjie Zhao, Zhaoming Wang, Dan Liu, Chenyu Tian, Botian Ye, Yihong Sun, Haojie Li, Xuefei Wang
International Journal of Surgery.2023; 109(12): 4151. CrossRef
The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer
Yiqi Fan, Shuai He
Cancer Management and Research.2022; Volume 14: 1. CrossRef
Peripheral node addressin, a ligand for L-selectin is found in tumor cells and in high endothelial venules in endometrial cancer
Georgia Karpathiou, Viviana Sramek, Sami Dagher, Mousa Mobarki, Maroa Dridi, Tiphanie Picot, Celine Chauleur, Michel Peoc’h
Pathology - Research and Practice.2022; 233: 153888. CrossRef
The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer
Bin Wang, Jie Liu, Yin Han, Yaotiao Deng, Jinze Li, Yu Jiang
Frontiers in Immunology.2022;[Epub] CrossRef
Role of tertiary lymphoid organs in the regulation of immune responses in the periphery
Amit I. Bery, Hailey M. Shepherd, Wenjun Li, Alexander S. Krupnick, Andrew E. Gelman, Daniel Kreisel
Cellular and Molecular Life Sciences.2022;[Epub] CrossRef
Tertiary Lymphoid Structures as Mediators of Immunotherapy Response
Raj G. Vaghjiani, Joseph J. Skitzki
Cancers.2022; 14(15): 3748. CrossRef
Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
Rita Ribeiro, Maria João Carvalho, João Goncalves, João Nuno Moreira
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef
Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis
Shiqi Li, Ying Zhang, Peigen Zhang, Shuijing Xue, Yu Chen, Lihua Sun, Rui Yang
The Breast.2022; 66: 97. CrossRef
Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer
Davide Massa, Anna Tosi, Antonio Rosato, Valentina Guarneri, Maria Vittoria Dieci
Cancers.2022; 14(19): 4885. CrossRef
The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer
In Hye Song, Young-Ae Kim, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, Yeon ho Choi, Heejae Lee, Jeong-Han Seo, Youngjin Cho, Sung Wook Jung, Hee Jeong Kim, Sei Hyun Ahn, Hee Jin Lee, Gyungyub Gong
Cancer Research and Treatment.2022; 54(4): 1111. CrossRef
High endothelial venules associated with better prognosis in esophageal squamous cell carcinoma
Hongmu Li, Lu Tang, Xue Han, Leqi Zhong, Wuyou Gao, Youfang Chen, Jinhua Huang, Zhesheng Wen
Annals of Diagnostic Pathology.2022; 61: 152051. CrossRef
Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes
Jing Chen, Jian Chen, Lie Wang
Journal of Zhejiang University-SCIENCE B.2022; 23(10): 812. CrossRef
Tertiary Lymphoid Structures: A Potential Biomarker for Anti-Cancer Therapy
Ji’an Zou, Yingzhe Zhang, Yue Zeng, Yurong Peng, Junqi Liu, Chaoyue Xiao, Fang Wu
Cancers.2022; 14(23): 5968. CrossRef
Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients
Yi-Xin Yin, Yi-Hong Ling, Xiao-Li Wei, Cai-Yun He, Bing-Zhi Wang, Chun-Fang Hu, Wen-Ping Lin, Run-Cong Nie, Jie-Wei Chen, Jin-Long Lin, Jie Zhou, Juan-Juan Xie, Jing-Ping Yun, Dan Xie, Li-Yan Xue, Mu-Yan Cai
Frontiers in Immunology.2022;[Epub] CrossRef
The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer
Stephanie L. Goff, David N. Danforth
Clinical Breast Cancer.2021; 21(1): e63. CrossRef
Immune microenvironment in different molecular subtypes of ductal breast carcinoma
Mona Sadeghalvad, Hamid-Reza Mohammadi-Motlagh, Nima Rezaei
Breast Cancer Research and Treatment.2021; 185(2): 261. CrossRef
Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes
Alfie T Baker, Mohammed H Abuwarwar, Lylarath Poly, Simon Wilkins, Anne L Fletcher
The Journal of Immunology.2021; 206(2): 310. CrossRef
Repenser la place des lymphocytes B et des structures lymphoïdes tertiaires dans l’immunothérapie des cancers
Claire Germain, Hélène Kaplon, Marie-Caroline Dieu-Nosjean
médecine/sciences.2021; 37(2): 130. CrossRef
High endothelial venules are present in pharyngeal and laryngeal carcinomas and they are associated with better prognosis
Georgia Karpathiou, Jean Marc Dumollard, Marie Gavid, Francois Casteillo, Marine Vieville, Jean Michel Prades, Marios Froudarakis, Michel Peoc’h
Pathology - Research and Practice.2021; 220: 153392. CrossRef
Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer
Hajime Kuroda, Tsengelmaa Jamiyan, Rin Yamaguchi, Akinari Kakumoto, Akihito Abe, Oi Harada, Bayarmaa Enkhbat, Atsuko Masunaga
Breast Cancer.2021; 28(4): 904. CrossRef
Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast
Hajime Kuroda, Tsengelmaa Jamiyan, Rin Yamaguchi, Akinari Kakumoto, Akihito Abe, Oi Harada, Atsuko Masunaga
BMC Cancer.2021;[Epub] CrossRef
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies
Jacquelot N, Tellier J, Nutt Sl, Belz Gt
OncoImmunology.2021;[Epub] CrossRef
High endothelial venules (HEVs) in immunity, inflammation and cancer
Lucas Blanchard, Jean-Philippe Girard
Angiogenesis.2021; 24(4): 719. CrossRef
Immunohistochemical analysis of L1 cell adhesion molecule and high endothelial venules in breast cancer brain metastasis
Georgia Karpathiou, Florian Camy, Jean Marc Dumollard, Michel Peoc’h
Pathology - Research and Practice.2021; 223: 153484. CrossRef
The Immunology of Hormone Receptor Positive Breast Cancer
Jonathan Goldberg, Ricardo G. Pastorello, Tuulia Vallius, Janae Davis, Yvonne Xiaoyong Cui, Judith Agudo, Adrienne G. Waks, Tanya Keenan, Sandra S. McAllister, Sara M. Tolaney, Elizabeth A. Mittendorf, Jennifer L. Guerriero
Frontiers in Immunology.2021;[Epub] CrossRef
Immune Crosstalk Between Lymph Nodes and Breast Carcinomas, With a Focus on B Cells
Elena Alberts, Isobelle Wall, Dinis Pedro Calado, Anita Grigoriadis
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation
Charlotte Domblides, Juliette Rochefort, Clémence Riffard, Marylou Panouillot, Géraldine Lescaille, Jean-Luc Teillaud, Véronique Mateo, Marie-Caroline Dieu-Nosjean
Frontiers in Immunology.2021;[Epub] CrossRef
The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures
Roger Li, Anders Berglund, Logan Zemp, Jasreman Dhillon, Ryan Putney, Youngchul Kim, Rohit K. Jain, G. Daniel Grass, José Conejo-Garcia, James J. Mulé
Frontiers in Immunology.2021;[Epub] CrossRef
Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
Alyssa Vito, Omar Salem, Nader El-Sayes, Ian P. MacFawn, Ana L. Portillo, Katy Milne, Danielle Harrington, Ali A. Ashkar, Yonghong Wan, Samuel T. Workenhe, Brad H. Nelson, Tullia C. Bruno, Karen L. Mossman
Communications Biology.2021;[Epub] CrossRef
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Shuyue Wang, Kun Xie, Tengfei Liu
Frontiers in Immunology.2021;[Epub] CrossRef
High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer
Gerlanda Vella, Sophie Guelfi, Gabriele Bergers
Frontiers in Immunology.2021;[Epub] CrossRef
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer
Robert J. Harris, Anthony Cheung, Joseph C.F. Ng, Roman Laddach, Alicia M. Chenoweth, Silvia Crescioli, Matthew Fittall, Diana Dominguez-Rodriguez, James Roberts, Dina Levi, Fangfang Liu, Elena Alberts, Jelmar Quist, Aida Santaolalla, Sarah E. Pinder, Che
Cancer Research.2021; 81(16): 4290. CrossRef
Tertiary lymphoid structure and B‑cell‑related pathways: A potential target in tumor immunotherapy (Review)
Meng Qin, Ying Jin, Ling-Ya Pan
Oncology Letters.2021;[Epub] CrossRef
Heterogeneity of Circulating Tumor Cell–Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response
Nisha Kanwar, Zaldy Balde, Ranju Nair, Melanie Dawe, Shiyi Chen, Manjula Maganti, Eshetu G. Atenafu, Sabrina Manolescu, Carrie Wei, Amanda Mao, Fred Fu, Dan Wang, Alison Cheung, Yulia Yerofeyeva, Rachel Peters, Kela Liu, Christine Desmedt, Christos Sotiri
Cancer Research.2021; 81(24): 6196. CrossRef
Oral cancer-associated tertiary lymphoid structures: gene expression profile and prognostic value
K Li, Q Guo, X Zhang, X Dong, W Liu, A Zhang, Y Li, J Yan, G Jia, Z Zheng, W Tang, L Pan, M An, B Zhang, S Liu, B Fu
Clinical and Experimental Immunology.2020; 199(2): 172. CrossRef
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink, Sangeetha M. Reddy, Jianjun Gao, Shaojun Zhang, Rafet Basar, Rohit Thakur, Keren Yizhak, Moshe Sade-Feldman, Jorge Blando, Guangchun Han, Vancheswaran Gopalakrishnan, Yuanxin Xi, Hao Zhao, Rodabe N. Amaria, Hussein A. Tawbi, Alex P. Cogdi
Nature.2020; 577(7791): 549. CrossRef
Neolymphogenesis and Immunogistogochemical Study of Lymph Nodes in Breast Cancer
Sh. Kh. Gantsev, R. A. Rustamkhanov, Sh. R. Kzyrgalin, D. S. Tursumetov
Creative surgery and oncology.2020; 9(4): 266. CrossRef
Duality of B Cell-CXCL13 Axis in Tumor Immunology
Angel J. Rubio, Tyrone Porter, Xuemei Zhong
Frontiers in Immunology.2020;[Epub] CrossRef
Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis
Zhao-hua Gao, Cun-xin Li, Ming Liu, Jia-yuan Jiang
BMC Cancer.2020;[Epub] CrossRef
Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy
Anthony B. Rodriguez, Victor H. Engelhard
Cancer Immunology Research.2020; 8(11): 1338. CrossRef
Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure
Ziying Lin, Lixia Huang, ShaoLi Li, Jincui Gu, Xiaoxian Cui, Yanbin Zhou
Scientific Reports.2020;[Epub] CrossRef
Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis
Miseon Lee, Sun-Hee Heo, In Hye Song, Hajar Rajayi, Hye Seon Park, In Ah Park, Young-Ae Kim, Heejae Lee, Gyungyub Gong, Hee Jin Lee
Modern Pathology.2019; 32(1): 70. CrossRef
Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
A. F. de Groot, E. J. Blok, A. Charehbili, C. C. Engels, V. T. H. B. M. Smit, N. G. Dekker-Ensink, H. Putter, E. Meershoek-Klein Kranenbarg, C. J. H. van de Velde, G. J. Liefers, J. W. R. Nortier, P. J. K. Kuppen, S. H. van der Burg, J. R. Kroep
Breast Cancer Research and Treatment.2019; 175(3): 605. CrossRef
The effect of C-X-C motif chemokine ligand 13 in cutaneous squamous cell carcinoma treated with aminolevulinic acid-photodynamic therapy
Lude Zhu, Guolong Zhang, Peiru Wang, Linglin Zhang, Jie Ji, Xiaojing Liu, Zhongxia Zhou, Jingjun Zhao, Xiuli Wang
Photodiagnosis and Photodynamic Therapy.2019; 26: 389. CrossRef
Tertiary lymphoid structures in the era of cancer immunotherapy
Catherine Sautès-Fridman, Florent Petitprez, Julien Calderaro, Wolf Herman Fridman
Nature Reviews Cancer.2019; 19(6): 307. CrossRef
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
Johannes Griss, Wolfgang Bauer, Christine Wagner, Martin Simon, Minyi Chen, Katharina Grabmeier-Pfistershammer, Margarita Maurer-Granofszky, Florian Roka, Thomas Penz, Christoph Bock, Gao Zhang, Meenhard Herlyn, Katharina Glatz, Heinz Läubli, Kirsten D. M
Nature Communications.2019;[Epub] CrossRef
Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer
Sangeetha M. Reddy, Alexandre Reuben, Souptik Barua, Hong Jiang, Shaojun Zhang, Linghua Wang, Vancheswaran Gopalakrishnan, Courtney W. Hudgens, Michael T. Tetzlaff, James M. Reuben, Takahiro Tsujikawa, Lisa M. Coussens, Khalida Wani, Yan He, Lily Villarea
Cancer Immunology Research.2019; 7(6): 1025. CrossRef
New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms
Meng Shen, Jian Wang, Xiubao Ren
Frontiers in Immunology.2018;[Epub] CrossRef
Hot Spot and Whole-Tumor Enumeration of CD8+ Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer
Patrick J. McIntire, Lina Irshaid, Yifang Liu, Zhengming Chen, Faith Menken, Eugene Nowak, Sandra J. Shin, Paula S. Ginter
Clinical Breast Cancer.2018; 18(6): 451. CrossRef
Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma
Tímea Sebestyén, Anita Mohos, Gabriella Liszkay, Beáta Somlai, István Gaudi, Andrea Ladányi
Melanoma Research.2018; 28(4): 304. CrossRef
Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer
Yunxuan Wang, Tieying Dong, Qijia Xuan, Hong Zhao, Ling Qin, Qingyuan Zhang
Journal of Breast Cancer.2018; 21(2): 124. CrossRef
Functions of the CXC ligand family in the pancreatic tumor microenvironment
Nien-Hung Lee, Mehrdad Nikfarjam, Hong He
Pancreatology.2018; 18(7): 705. CrossRef
Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer
Soizic Garaud, Pawel Zayakin, Laurence Buisseret, Undine Rulle, Karina Silina, Alexandre de Wind, Gert Van den Eyden, Denis Larsimont, Karen Willard-Gallo, Aija Linē
Frontiers in Immunology.2018;[Epub] CrossRef
Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer
Maartje C.A. Wouters, Brad H. Nelson
Clinical Cancer Research.2018; 24(24): 6125. CrossRef
The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities
Nicole J. Flynn, Rajasekharan Somasundaram, Kimberly M. Arnold, Jennifer Sims-Mourtada
Targeted Oncology.2017; 12(2): 139. CrossRef
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Chunyan Gu-Trantien, Edoardo Migliori, Laurence Buisseret, Alexandre de Wind, Sylvain Brohée, Soizic Garaud, Grégory Noël, Luan Dang C.V., Jean-Nicolas Lodewyckx, Céline Naveaux, Hugues Duvillier, Stanislas Goriely, Denis Larsimont, Karen Willard-Gallo
JCI Insight.2017;[Epub] CrossRef
Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?
Emily Jayne Colbeck, Ann Ager, Awen Gallimore, Gareth Wyn Jones
Frontiers in Immunology.2017;[Epub] CrossRef
Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers
Xia Liu, Julia Y.S. Tsang, Thazin Hlaing, Jintao Hu, Yun-Bi Ni, Siu Ki Chan, Sai Yin Cheung, Gary M. Tse
The Oncologist.2017; 22(11): 1316. CrossRef

15,953 View
569 Download
104 Web of Science
98 Crossref

Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Management of Malignant Pleural Effusion: Kee Won Kim, Suk Young Park, Myung Sook Kim, Seok Chan Kim, Eun Hee Lee, So Young Shin, Jong Ho Lee, Jong Bum Kweon, Kuhn Park; Cancer Res Treat. 2004;36(1):68-71. Published online February 29, 2004; DOI: https://doi.org/10.4143/crt.2004.36.1.68

Abstract PDF PubReader ePub

Purpose

The purpose of this study was to evaluate the efficacy of intrapleural chemotherapy (IPC) with cisplatin and cytarabine in the management of malignant pleural effusion (MPE) from non-small-cell lung cancer (NSCLC).

Materials and Methods

A prospective analysis was carried out on 40 patients with pathologically proven MPE from NSCLC who had received IPC. A single dose of cisplatin 100 mg/m² plus cytarabine 1200 mg/m² in 250 ml normal saline was instilled into the pleural space via a chest tube and drained 4 hours later. Patients were evaluated for toxicities and responses at 1, 2, & 3 weeks and then at monthly intervals if possible. Systemic chemotherapy was administered, if the patient agreed to receive it, after achieving complete control (CC) of MPE.

Results

The median duration of chest tube insertion for drainage was 7 (3~32) days. Among the assessable 37 patients, CC and partial control (PC) were 32 (86.5%) and 4 (10.8%) patients, respectively (overall response rate 97.3%). The median duration of response was 12 months (2~23) and there were only two relapses of IPC after achieving CC. Among the 35 patients who were assessable until they died, 28 patients (80.0%) maintained CC until the last follow-up. There was only one toxic death and the toxicities of IPC, versus the results obtained, were deemed acceptable.

Conclusion

The procedures were tolerable to the patients and chemotherapy-induced complications were at an acceptable level. The outcome of this trial indicates that IPC has a superior and long lasting treatment response in the management of patients with MPE from NSCLC.

Citations

Citations to this article as recorded by

Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
Scientific Reports.2023;[Epub] CrossRef
Survival Benefits for Pulmonary Adenocarcinoma With Malignant Pleural Effusion After Thoracoscopic Surgical Treatment: A Real-World Study
Xin Li, Mingbiao Li, Jinshuang Lv, Jinghao Liu, Ming Dong, Chunqiu Xia, Honglin Zhao, Song Xu, Sen Wei, Zuoqing Song, Gang Chen, Hongyu Liu, Jun Chen
Frontiers in Oncology.2022;[Epub] CrossRef
Modified indwelling pleural catheter versus silver nitrate pleurodesis for the management of malignant pleural effusion
Mohammed F. Abdelghany, Khaled Essmat, Atef Farouk El-Karn, Sahar Farghly Youssif
The Egyptian Journal of Chest Diseases and Tuberculosis.2022; 71(2): 248. CrossRef
Chinese herbal injections versus intrapleural cisplatin for lung cancer patients with malignant pleural effusion: A Bayesian network meta-analysis of randomized controlled trials
Yi-Fang Xu, Yun-Ru Chen, Fan-Long Bu, Yu-Bei Huang, Yu-Xin Sun, Cheng-Yin Li, Jodi Sellick, Jian-Ping Liu, Dan-Mei Qin, Zhao-Lan Liu
Frontiers in Oncology.2022;[Epub] CrossRef
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
OncoImmunology.2019; 8(4): e1554969. CrossRef
Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion
Mohammad K. El Badrawy, Raed El-Metwally Ali, Asem A. Hewidy, Mohamed A. El-Layeh, Fatma M. F. Akl, Abdelhadi Shebl
Egyptian Journal of Bronchology.2018; 12(1): 98. CrossRef
Biodegradable drug-eluting pellets provide steady and sustainable cisplatin release in the intrapleural cavity: In vivo and in vitro studies
Yin-Kai Chao, Yu-Wen Wen, Kuo-Sheng Liu, Yi-Chuan Wang, Chih-Wei Wang, Shih-Jung Liu
International Journal of Pharmaceutics.2015; 484(1-2): 38. CrossRef

9,272 View
58 Download
7 Crossref

Expression of P53, Bcl-2, Bax, and P-glycoprotein in Relation to Chemotherapeutic Response in Patients with Advanced Non-Small-Cell Lung Cance: Suk Young Park, Eun Hee Lee, Kee Won Kim, Chul Seung Kay, Seok Chan Kim, Ji Won Suhr, Kyung Shick Lee; J Korean Cancer Assoc. 2001;33(2):158-162.

Abstract PDF: PURPOSE
To evaluate the relationship between the expressions of p53, bcl-2, bax, and p-glycoprotein and the chemotherapeutic response seen in patients with advanced NSCLC.
MATERIALS AND METHODS
Forty-four patients pathologically proven as NSCLC were reviewed. They had undergone at least two cycles of the same chemotherapeutic agents (cisplatin 60 mg/m2 day 1+ vinorelbine 25 mg/m2 day 1, 8, 21-day cycle) and the clinical response was evaluated by WHO criteria. The expressions of p53, bcl-2, bax, and p-glycoprotein were determined by immunohistochemistry.
RESULTS
Patients recorded as CR (2/44) and PR (20/44) were classified as the responder group (22/44) and stable (17/44) and progression (5/44) as the non-responder group (22/44). Positive expression of p53, bcl-2, bax, and p-glycoprotein were 84.1%, 65.9%, 88.6%, and 61.4% respectively. The expression score of p53 was significantly higher in the non-responder group than that seen in the responder group (8.59+/-1.89 vs 5.32+/-2.15, p<0.05). However, the expression scores of bcl-2, bax, and p-glycoprotein were not significantly correlated with the clinical response.
CONCLUSION
This study suggests that p53 gene mutation plays an important role in the clinical response to chemotherapy including cisplatin and vinorelbine. In future investigations, the correlation with the survival time will be studied.

3,369 View
30 Download

Combination Chemotherapy with Cisplatin and Vinorelbine in Patients with Non-Small-Cell Lung Cancer: Kee Won Kim, Suk Young Park, Ji Won Suhr, Seung Joon Kim, Dong Hoen Yang, Eun Hee Lee, Kyung Shick Lee; J Korean Cancer Assoc. 2000;32(5):911-917.

Abstract PDF: PURPOSE
To determine the therapeutic effect and toxicities of cisplatin and vinorelbine combination chemotherapy in patients with inoperable non-small-cell lung cancer.
MATERIALS AND METHODS
Between Jan 1998 and Dec 1999, 28 patients with inoperable non- small-cell lung cancer were treated with cisplatin and vinorelbine combination chemotherapy as induction treatment. A combination of vinorelbine 25 mg/m2 day 1,8 and cisplatin 60 mg/m2 day 1 were given and repeated every 3 weeks. Then we assessed response and toxicity according to WHO grades.
RESULTS
According to response criteria, there were 1 complete response, 12 partial response (42.9%), 12 stable disease (42.9%), and 3 progression (10.7%). The median survival was 12 months. According to toxicity grades, 24 grade 3 myelosuppression (24.7%), 12 grade 4 myelo suppression (10.7%), 6 grade 3 and 4 constipation (6.1%), and mild 7 (7.2%) thrombophlebitis were experienced in evaluable 97 cycles. There was no other clinically severe toxicity.
CONCLUSION
These results suggest that combination chemotherapy with cisplatin and vinorelbine in patients with inoperable non-small-cell lung cancer was effective and safe.

2,947 View
17 Download

The Site-dependent Differences in Response to Chemotherapy in Patients with Advanced Lung Cancer: Kee Won Kim, Sook Kyung Lee, Jee Won Seo, Suk Young Park, Kyung Shik Lee; J Korean Cancer Assoc. 1999;31(3):533-538.

Abstract PDF: PURPOSE
To detennine the extent and the clinical significance of site-dependent differences in response to chemotherapy in patients with metastatic lung cancer.
MATERIALS AND METHODS
We reviewed the records of patients with metastatic lung cancer who had received chemotherapy and were evaluated for the response of primary lung and metastatic lesions simultaneously. Total 52 patients were eligible.
RESULTS
The discordance rate of response between primary lung lesion and various metastatic lesions was 0% (0/51) at regional lymph nodes, 12% (1/8) at distant lymph nodes, 45% (5/11) at hematogenous metastatic lung lesion, 0% (0/7) at liver, 50% at adrenal glands, and 21% (3/14) at bone. As a result, the concordance rate of response amang lymph nodes, liver, and primary lung lesions was high. But some differences in response were observed at intrapulmonary metastatic lesion, adrenal glands, and bone lesions in comparison with primary lung lesion.
CONCLUSION
We conclude that the effective therapeutic strategies against those discordant metastatic lesions should be developed to increase the overall treatment effect in patients with metastatic lung cancer.

2,320 View
13 Download

The Treatment of Malignant Bronchial Obstruction by Laser Photoablation: Suk Young Park, Wan Wuk Kim; J Korean Cancer Assoc. 1996;28(3):483-490.

Abstract PDF: Background
Bronchial obstruction by advanced lung cancer is troublesome. Radiation therapy has been the choice of treatment, but it may take the long time until relieving obstruction and cause severe complications. To evaluate the clinical effect and complication of laser photoablation, we performed photoablation with Nd-YAG laser in the patients with malignant bronchial obstruction. Methods: Twenty five patients with advanced lung cancer(24)and bronchial cystic carcinoma(l) were treated with laser photoablation for the symptomatic palliation of life- threatening bronchial obstruction from 1990 to 1994, in Daejeon St Mary's Hospital of Catholic University Medical Colledge. Results: The degree of bronchial obstruction and the performance status scales were markedly improved within a few days after laser photoablation. The degree of bronchial obstruction was reduced in twenty three cases(92%) and the Performance Status by Karnofsky Scales was improved from less than 30 to more than 50 in twenty one cases(84 %) after laser photoablation. Threre was no serious complication and no procedure-related mortality. Complications were as follows; fever(28%) and mild hemoptysis(16%). Conclusion: Laser photoablation is an effective therapeutic modality for the palliation of bronchial obstruction caused by advanced lung cancer. The procedure is very tolerable and safe without serious complication.

2,253 View
12 Download

Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Manabement of Malignant Pleural Effusion: Suk Young Park, Baik Jong Seo; J Korean Cancer Assoc. 1996;28(4):698-705.

Abstract PDF: Malignant pleural effusion is a common snd signigicant problem in patients with advanced malignancies. The optimal means of control are not defined. Pleurodesis with tetracycline or other sclerosing agents has been the usual treatment for malignant pleural effusions. Intracavitary cisplatin-based chemotherapy has been recently reported to be successful in some clinical trials for the purpose of controlling malignant exudate and favored by some authors because it is thought to be cytotoxic rather than sclerosing, that is, the potential advantage of treating the underlying malignancy in addition to controlling the effusion. This study evaluated intrapleural cisplatin and cytarabine combination chemotherapy in 15 patients with malignant pleural effusions from lung and other cancers. A single dose of cisplatin plus cytarabine was instilled into pleural space via a chest tube and drained 4 hours later. Systemic chemotheapy and/or radiation therapy were given at least 3 weeks apart after intrapleural chemotherapy if decided to recieve them. The outcome of this trial indicated that the intrapleural chemotherapy had high and durable treatment response(87%; CR 13 cases(81%)) and the median duration of response was 29 weeks which seemed long enough to be little maiignant pieural effusion in 7 cases among 9 patients followed up till moribund state. The procedures were tolerable in all the cases and chemothrapy induced complications were not significant.

2,831 View
20 Download

First
Prev
Page of 1
Next
Last

Search